Key Companies: Osteoporosis - Growing Competition Threatens Leading Franchises and Drives Innovation
NEW YORK, Aug. 10, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Key Companies: Osteoporosis - Growing competition threatens leading franchises and drives innovation
http://www.reportlinker.com/p0591221/Key-Companies-Osteoporosis---Growing-competition-threatens-leading-franchises-and-drives-innovation.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Introduction
The osteoporosis market is dominated by large pharmaceutical companies that can leverage their considerable financial reserves to conduct large-scale clinical trials, and which have the marketing strength needed to penetrate this sector. Osteoporosis companies market one or two drugs for which they promote safety and patient convenience, and pursue indication expansions.
Features and benefits
* In-depth discussion of brand lifecycle and portfolio management strategies of key companies involved in the osteoporosis market.
* Review Merck & Co.'s and Servier's osteoporosis portfolio management strategies and what challenges these companies are facing.
* Assess trends in corporate strategies of companies active in the osteoporosis arena and understand the impact of key recent licensing deals.
* Identify the leading companies involved in osteoporosis and how their franchises have been performing over 2005–10.
* Learn how companies can respond to future opportunities and challenges in the field.
Highlights
Developing new technologies to improve compliance remains a popular portfolio management strategy in the osteoporosis market and the latest opportunity is for more conveniently dosed and administered anabolic drugs.
Merck lost its market leading position due to generic erosion. With two novel therapies in development, the company now has an opportunity to restore its market share. However, the main challenge is to bring these drugs to market while maintaining relationships with key osteoporosis stakeholders.
Servier has so far maintained a successful standing in Europe by promoting Protelos (strontium ranelate) as a novel effective and safe alternative therapy to bisphosphonates. However, in spite of the possible launch of a follow-on product, long term growth prospects will be hindered by future competition from generic strontium ranelate.
Your key questions answered
* Which are the leading companies in the osteoporosis market?
* How successful are the portfolio management strategies most widely used in the osteoporosis market?
* How is Merck & Co. attempting to regain its leading position?
* What makes Servier's osteoporosis offering unique?
* What are the main challenges companies are facing in this therapy area?
Executive Summary
Strategic scoping and focus
Datamonitor key findings
Related reports
OVERVIEW
Catalyst
Summary
COMPANY STRATEGIES
Strategic overview
Trends in corporate strategy
Developing anabolic treatments becomes a priority in the market
Reformulations are popular brand lifecycle extension strategies
Indication expansions increase the market potential of osteoporosis drugs
Multiple therapy offerings can increase returns and lower risk
Dosing convenience as a unique selling point of their brands
Recent strategic partnerships and deals
Nycomed bolsters Takeda's osteoporosis portfolio
Warner Chilcott's women's health expertise will help build its presence in the osteoporosis market
MERCK & CO.
Corporate strategy
Osteoporosis portfolio assessment
Merck loses its market leading position due to poor portfolio management strategy
High risk first-in-class pipeline products will reward Merck
SWOT analysis for Merck's osteoporosis portfolio
LES LABORATOIRES SERVIER
Corporate strategy
Osteoporosis portfolio assessment
Servier promotes safety data to exploit concerns regarding other therapies
Servier in-licenses NBS101 to maintain its osteoporosis franchise but this is unlikely to be sufficient
Servier shows commitment to the European osteoporosis community
SWOT analysis for Servier's osteoporosis portfolio
PORTFOLIO REVIEW OF OTHER LEADING COMPANIES
Novartis
Continued interest in the market is reflected in the pipeline activity
Amgen
Investing heavily in building its presence in the osteoporosis community to drive Prolia's uptake
Amgen is developing a novel anabolic compound
Pfizer
Pfizer attempts to redefine the SERM market
Eli Lilly
Eli Lilly to lose leading position due to poor pipeline
GlaxoSmithKline
GlaxoSmithKline maintains interest in the osteoporosis market
BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports
APPENDIX
PharmaVitae Explorer database
Conferences attended
Report methodology
To order this report:
Pathology Industry: Key Companies: Osteoporosis - Growing competition threatens leading franchises and drives innovation
Pathology Business News
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article